Back to Search
Start Over
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
- Source :
-
Circulation . 8/23/2022, Vol. 146 Issue 7, p652-654. 3p. - Publication Year :
- 2022
-
Abstract
- Keywords: cardiovascular diseases; diabetes mellitus, type 2; metformin; sodium-glucose transporter 2 inhibitors EN cardiovascular diseases diabetes mellitus, type 2 metformin sodium-glucose transporter 2 inhibitors 652 654 3 08/22/22 20220823 NES 220823 The universal guidance of treating patients with type 2 diabetes (T2D) with metformin first has been questioned since positive cardiovascular outcomes trials of antihyperglycemic agents were reported between 2015 and 2021, demonstrating cardiovascular efficacy of multiple glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Sources of Funding This study was sponsored by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, in collaboration with Pfizer Inc., New York, NY. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00097322
- Volume :
- 146
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 158599091
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.121.058294